LIFE BioCEEd has announced its first investment — into a pioneering gene therapy developed by scientists from the Institute of Molecular Genetics of the Czech Academy of Sciences. The research focuses on finding a cure for Netherton syndrome, a rare and severe genetic skin disease affecting approximately one in 200,000 newborns worldwide.

The therapy, developed under the leadership of Assoc. Prof. Radislav Sedláček, aims to replace the damaged gene directly in skin cells, targeting the root cause of the disease. Preclinical results have already shown significant progress, opening the path toward potential clinical application.

“Our innovative therapy replaces the defective gene directly in the patient’s skin cells, addressing the main cause of the disease. This represents a major step forward in treating Netherton syndrome,” said Sedláček.

This project marks LIFE BioCEEd’s first investment from its €20 million venture capital platform, dedicated to advancing medical biotechnologies from early-stage research to commercialization.

As CEO Stefan Savić notes, “Our mission is to identify breakthrough technologies that go beyond symptom management — addressing the root cause of disease.”

Gene therapy remains one of the most challenging yet promising fields in modern medicine. By investing in  projects like this, LIFE BioCEEd strengthens the bridge between Czech scientific excellence and global biomedicine, helping transform innovative research into therapies that can change lives.

Read the full article:

Investors support Czech research into a drug for a rare childhood disease – Seznam Zprávy